Slingshot members are tracking this event:

Phase 3 data of AbbVie's(ABBV) Risankizumab in Psoriasis due by the end of 2017 due by the end of 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ABBV Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase Iii Study, Risankizumab, Psoriasis